DEXCOM INC
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 2. Properties
We lease real property throughout the world to support our business, including manufacturing, research and development, sales, marketing and administration. We believe our facilities are suitable and adequate for our current and near-term needs, and that we will be able to locate additional facilities as needed. The following table sets forth the locations of our corporate headquarters and manufacturing facilities:
| Location | Purpose |
|---|---|
| San Diego, California | Corporate headquarters, research and development, and manufacturing |
| Mesa, Arizona | Manufacturing |
| Penang, Malaysia | Manufacturing |
| Athenry, Ireland(1) | Manufacturing |
| (1) Our new manufacturing facility in Athenry, Ireland is under construction. | |
As of December 31, 2025, we had approximately 79,700 square feet of laboratory space and approximately 159,600 square feet of controlled environment rooms. See Note 5 “Leases and Other Commitments” to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.